PATENT CLAIM ANALYSIS

Application Number: 15880180
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "275000"]

Abstract:
The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.

Claim (Index 4):
The pharmaceutical solution of  claim 1 , wherein the ophthalmic therapeutic agent has a solubility of less than 0.01 mg/mL in water.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 86.0
- Lexical Diversity: 1.46667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15270493', '14819682', '14212817', '13664133', '13909670']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8056132976453639
- 35 USC 102 Novelty (BERT): 0.591358628216844
- Combined Prediction Score: 0.784187830702512
- Mean Citation Score: 381.23133
- Max Citation Score: 540.7341299999998
- Similarity Product: 424.23615852131366

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test